MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fendo.2026.1747769

Медицинская библиотека · Frontiers in endocrinology · 2026

Efficacy and safety of 125I seed implantation combined with thyroid-stimulating hormone suppression therapy in cervical lymph node metastases of differentiated thyroid carcinoma.

Ruan Yi, Yuan Hui, Zheng Feng, Yang Yang, Chen Xuehua, Xu Cheng

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Differentiated thyroid carcinoma (DTC) is a common endocrine malignancy, and cervical lymph node metastasis (LNM) represents the predominant pattern of disease recurrence. For patients who develop persistent or recurrent cervical lesions following total thyroidectomy and radioactive iodine (131I) therapy, conventional reoperation or additional 131I therapy often provides limited efficacy and may carry increased procedural risks.

METHODS

This single-center retrospective cohort study included 238 patients with persistent or recurrent cervical LNM after prior thyroidectomy and 131I therapy who were treated between January 2020 and January 2024. Among them, 118 patients received 125I seed implantation with thyroid-stimulating hormone (TSH) suppression. After 1:1 propensity score matching (PSM), 110 patients were included in each group for analysis. Short-term efficacy, thyroglobulin (Tg), radiologic changes, dosimetric consistency, survival outcomes, and adverse events were compared. Dynamic changes in Tg levels and the short-axis diameter of LNM were analyzed using a linear mixed-effects model.

RESULTS

After PSM, the partial response rates at 6 and 12 months were significantly higher in the 125I+TSH group. 125I+TSH therapy was an independent predictor of partial response. Patients in the 125I+TSH group exhibited a faster decline in Tg levels, with an average reduction of approximately 14.5% per month and a reduction in the short-axis diameter of LNM of 4.8% per month, corresponding to biochemical and morphological half-lives of 4.4 and 14.2 months, respectively. The overall incidence of adverse events was low.

CONCLUSIONS

125I seed implantation combined with TSH suppression therapy accelerates Tg decline and lesion regression and demonstrates good safety.

Для цитирования: Ruan Yi, Yuan Hui, Zheng Feng, Yang Yang, Chen Xuehua, Xu Cheng. Efficacy and safety of 125I seed implantation combined with thyroid-stimulating hormone suppression therapy in cervical lymph node metastases of differentiated thyroid carcinoma.. Frontiers in endocrinology. 2026. DOI: 10.3389/fendo.2026.1747769.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.